The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

Abstract

Fifty-one patients with primary myelofibrosis (PMF) received allogeneic haematopoietic stem cell transplants from related (n=33) or unrelated (n=18) donors. Twenty-seven patients, 19-54 years old, were prepared with myeloablative regimens including CY plus BU (n=4) or TBI (n=23). Twenty-four patients, 40-64 years old, received reduced-intensity conditioning (RIC) regimens. All RIC regimens contained fludarabine, combined with melphalan (n=19) or BU (n=5), and alemtuzumab or anti-thymocyte globulin (ATG) in the majority (n=19). Four patients (17%) in the RIC group had primary graft failure. Previous splenectomy reduced time to engraftment in the RIC group (13 versus 20 days; P=0.008). For MA and RIC groups, respectively, at 3 years, overall survival rates were 44 and 31% (P=0.67), progression-free survival 44 and 24% (P=0.87), and actuarial relapse rates 15 and 46% (P=0.06). Non-relapse mortality at 3 years was 41% for the myeloablative and 32% for the RIC group. Acute GVHD occurred in 29 and 38% of patients in the myeloablative and RIC groups, respectively. Extensive chronic GVHD developed in 30 and 35% of evaluable patients, respectively.

• Authors: W A Stewart, R Pearce, K E Kirkland, A Bloor, K Thomson, J Apperley, G McQuaker, D I Marks, C Craddock, S McCann, N Russell, G Cook, P D Kottaridis, British Society for Blood and Marrow Transplantation
• Journal: Bone marrow transplantation (Bone Marrow Transplant) Vol. 45 Issue 11 Pg. 1587-93 (Nov 2010) ISSN: 1476-5365 [Electronic] England
• PMID: 20154739 (Publication Type: Journal Article)

Topics

• Adult
• Female
• Humans
• Male
• Middle Aged
• Peripheral Blood Stem Cell Transplantation (methods)
• Primary Myelofibrosis (surgery)
• Retrospective Studies
• Transplantation Conditioning
• Transplantation, Homologous
• Young Adult